scholarly journals Progressive Supranuclear Palsy-a Mirror Image of Parkinson’s Disease, A Literature Review of Rehabilitation Strategies

Author(s):  
Arpita Shetty ◽  
K. M. Krishnaprasad

Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease which mimic similar to Parkinsonism. PSP advances much quicker than in PD yet no effective medication or therapy to manage PSP available. This literature review aimed to discover the recent advances in the physical therapy treatment options for PSP. Databases such as PubMed, Elsevier and SAGE journal searched for both published and unpublished studies. Last 10-year studies were included in this review. Limited clinical trial conducted in this population due to which a structured protocol or rehabilitation strategies is missing for this condition. Balance exercise and gait training showed potential benefit and music-cued walking demonstrated participant’s satisfaction.

2021 ◽  
Vol 2 (2) ◽  
Author(s):  
Irwin S. Thompson

Injury to the infrapatellar branch of the saphenous nerve (IBSN) is an underreported condition which has important implications for the physical therapist. Due to its location, the IBSN is especially vulnerable to damage following surgery, but it may also be injured through trauma or unknown causes. Patients with suspected IBSN injury may present with a variety of symptoms, including pain along the nerve distribution, paresthesia, hypoesthesia, anesthesia, and impaired functional activities and mobility. As the presence of IBSN injury may not be readily apparent, it is incumbent upon the physical therapist to recognize the signs and symptoms associated with this condition, and to administer a detailed clinical examination. Clinical evaluation can be difficult, as IBSN injury mimics many other conditions of the knee. Additionally, saphenous nerve anatomy exhibits wide variance, even within individuals, making diagnosis challenging. Upon suspicion of IBSN injury, the physical therapist should refer the patient for a comprehensive medical exam, which may include nerve blocks, nerve conduction studies, MRI, CT scan, or exploratory surgery. Most patients respond well to surgical intervention, including neurolysis or neurectomy, though conservative treatment options exist. These include nerve blocks or pharmacologic interventions. Physical therapy treatment is not well reported and may only be appropriate for specific etiologies of injury.


2010 ◽  
Vol 23 (1) ◽  
pp. 31-37 ◽  
Author(s):  
Christy C. Tomkins ◽  
Katherine H. Dimoff ◽  
Holly S. Forman ◽  
Emily S. Gordon ◽  
Jennifer McPhail ◽  
...  

CNS Drugs ◽  
2016 ◽  
Vol 30 (7) ◽  
pp. 629-636 ◽  
Author(s):  
Maria Stamelou ◽  
Günter Höglinger

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Huai Leng Pisaniello ◽  
Mark C. Fisher ◽  
Hamish Farquhar ◽  
Ana Beatriz Vargas-Santos ◽  
Catherine L. Hill ◽  
...  

AbstractGout flare prophylaxis and therapy use in people with underlying chronic kidney disease (CKD) is challenging, given limited treatment options and risk of worsening renal function with inappropriate treatment dosing. This literature review aimed to describe the current literature on the efficacy and safety of gout flare prophylaxis and therapy use in people with CKD stages 3–5. A literature search via PubMed, the Cochrane Library, and EMBASE was performed from 1 January 1959 to 31 January 2018. Inclusion criteria were studies with people with gout and renal impairment (i.e. estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) < 60 ml/min/1.73 m2), and with exposure to colchicine, interleukin-1 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids. All study designs were included. A total of 33 studies with efficacy and/or safety analysis stratified by renal function were reviewed—colchicine (n = 20), anakinra (n = 7), canakinumab (n = 1), NSAIDs (n = 3), and glucocorticoids (n = 2). A total of 58 studies reported these primary outcomes without renal function stratification—colchicine (n = 29), anakinra (n = 10), canakinumab (n = 6), rilonacept (n = 2), NSAIDs (n = 1), and glucocorticoids (n = 10). Most clinical trials excluded study participants with severe CKD (i.e. eGFR or CrCl of < 30 mL/min/1.73 m2). Information on the efficacy and safety outcomes of gout flare prophylaxis and therapy use stratified by renal function is lacking. Clinical trial results cannot be extrapolated for those with advanced CKD. Where possible, current and future gout flare studies should include patients with CKD and with study outcomes reported based on renal function and using standardised gout flare definition.


2021 ◽  
pp. 153857442110024
Author(s):  
Rozina Yasmin Choudhury ◽  
Kamran Basharat ◽  
Syeda Anum Zahra ◽  
Tien Tran ◽  
Lara Rimmer ◽  
...  

Over the decades, the Frozen Elephant Trunk (FET) technique has gained immense popularity allowing simplified treatment of complex aortic pathologies. FET is frequently used to treat aortic conditions involving the distal aortic arch and the proximal descending aorta in a single stage. Surgical preference has recently changed from FET procedures being performed at Zone 3 to Zone 2. There are several advantages of Zone 2 FET over Zone 3 FET including reduction in spinal cord injury, visceral ischemia, neurological and cardiovascular sequelae. In addition, Zone 2 FET is a technically less complicated procedure. Literature on the comparison between Zone 3 and Zone 2 FET is scarce and primarily observational and anecdotal. Therefore, further research is warranted in this paradigm to substantiate current surgical treatment options for complex aortic pathologies. In this review, we explore literature surrounding FET and the reasons for the shift in surgical preference from Zone 3 to Zone 2.


2021 ◽  
Vol 10 (13) ◽  
pp. 2963
Author(s):  
Corina Kim-Fuchs ◽  
Daniel Candinas ◽  
Anja Lachenmayer

Background: The incidence and mortality of intrahepatic cholangiocarcinoma (ICCA) is increasing worldwide and curative treatment options are limited due to the aggressive tumor biology and often late diagnosis. Resection of the primary tumor remains the only curative therapy available, as the benefit of palliative chemotherapy and radiotherapy is relatively small. In contrast to hepatocellular carcinoma, minimal-invasive thermal tumor ablation, and in particular stereotactic tumor ablation for small primary cancers or metastases, is not established and data are scarce. Methods: We conducted a literature review in the field of ICCA ablation and retrospective analysis of 10 patients treated by stereotactic microwave ablation (SMWA) for either primary ICCA or liver metastases of ICCA. Results: While current guidelines have no consensus for ablation of primary ICCA, some state that it might be an option in inoperable patients or those with recurrent disease. The literature review revealed 11 studies on microwave ablation for ICCA reporting that MWA for ICCA ≤ 5 cm might be safe and could be a treatment option for patients who are not candidates for surgery. No data has been published on stereotactic microwave ablation (SMWA) for ICCA. The analyses of our own data of 10 patients treated by SMWA for primary ICCA (n = 5) or recurrent ICCA (n = 5) show that the treatment is safe and efficient with short hospital stays and low complication rates. Conclusion: Although thermal ablation, and in particular SMWA, might be a minimally invasive and tissue-sparing curative treatment alternative for small ICCA in the diseased liver and ICCA metastases, the oncologic benefit still needs to be shown in larger studies with longer follow-up.


2008 ◽  
Vol 16 (4) ◽  
pp. 212-220 ◽  
Author(s):  
Troy J. Bourgeois ◽  
J. Randy Hernandez ◽  
Brett M. Cascio

Sign in / Sign up

Export Citation Format

Share Document